U.S. markets open in 3 hours 9 minutes
  • S&P Futures

    3,796.00
    -20.75 (-0.54%)
     
  • Dow Futures

    31,125.00
    -111.00 (-0.36%)
     
  • Nasdaq Futures

    12,594.00
    -87.75 (-0.69%)
     
  • Russell 2000 Futures

    2,186.50
    -19.30 (-0.87%)
     
  • Crude Oil

    60.96
    -0.32 (-0.52%)
     
  • Gold

    1,714.00
    -1.80 (-0.10%)
     
  • Silver

    25.98
    -0.41 (-1.54%)
     
  • EUR/USD

    1.2045
    -0.0022 (-0.18%)
     
  • 10-Yr Bond

    1.4700
    0.0000 (0.00%)
     
  • Vix

    27.39
    +3.29 (+13.65%)
     
  • GBP/USD

    1.3935
    -0.0017 (-0.13%)
     
  • USD/JPY

    107.3400
    +0.3380 (+0.32%)
     
  • BTC-USD

    49,290.59
    -2,221.79 (-4.31%)
     
  • CMC Crypto 200

    988.65
    +1.44 (+0.15%)
     
  • FTSE 100

    6,609.78
    -65.69 (-0.98%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Chardan Capital Sticks to Their Buy Rating for Solid Biosciences Llc

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.


Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Solid Biosciences (NASDAQ:SLDB) Llc on Saturday, setting a price target of $5, which is approximately 104.08% above the present share price of $2.45.

Amusa expects Solid Biosciences Llc to post earnings per share (EPS) of -$0.65 for the second quarter of 2020.

The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Solid Biosciences, with an average price target of $5.
The analysts price targets range from a high of $5 to a low of $5.

In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $0 and a net profit of -$32.33 million. The company's market cap is $115.64 million.

According to TipRanks.com, Chardan Capital analyst Gbola Amusa is a 5-star analyst with an average return of 27.1% and a 52.1% success rate.

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.